Overexpression of RNF126 is associated with poor prognosis and contributes to the progression of lung adenocarcinoma

Biomark Med. 2021 Oct;15(15):1345-1355. doi: 10.2217/bmm-2020-0798. Epub 2021 Sep 17.

Abstract

Aim: To document the expression and function of RNF126 in lung adenocarcinoma (LAD). Materials & methods: A total of 102 LAD patients were enrolled in this retrospective study. The mRNA and protein levels of RNF126 were tested via RT-qPCR and immunohistochemical staining, respectively. Univariate and multivariate analyses were conducted to exploring the clinical significance of RNF126 in the prognosis. Knockdown and overexpression strategies were used to validate the tumor-related roles of RNF126 both in vitro and in vivo. Results: RNF126 was highly expressed and was an independent predictor of a poor prognosis for LAD patients. We also revealed that RNF126 knockdown suppressed proliferation of LAD cells and xenografts. Conclusion: RNF126 is a potential survival predictor and therapeutic target for LAD.

Keywords: lung cancer; prognosis; ubiquitination.

MeSH terms

  • A549 Cells
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / therapy
  • Animals
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Cell Movement / genetics
  • Cell Survival / genetics
  • Disease Progression
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / therapy
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Prognosis
  • RNAi Therapeutics / methods
  • Retrospective Studies
  • Ubiquitin-Protein Ligases / genetics*
  • Ubiquitin-Protein Ligases / metabolism
  • Xenograft Model Antitumor Assays / methods

Substances

  • Biomarkers, Tumor
  • RNF126 protein, human
  • Ubiquitin-Protein Ligases